Avutometinib (NCT06007924)

Name: Avutometinib trial for Thyroid Cancer (NCT06007924)
Uploaded: 2026-10-31T21:21:33.579Z
Duration: 1 min 27 s
Description: Avutometinib trial for Thyroid Cancer (NCT06007924). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06007924.

A Study of Avutometinib and Defactinib in People With Thyroid Cancer: a one-minute explainerNCT060079241 min

Avutometinib trial for Thyroid Cancer (NCT06007924). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with specified RAF-pathway alterations and either progressive, recurrent or metastatic, radioiodine-refractory differentiated thyroid cancer, or anaplastic thyroid cancer. Anaplastic cancers with BRAF V600E/K/D/R require previous BRAF-targeted treatment.

The idea: oral avutometinib blocks RAF/MEK signaling; defactinib blocks FAK signaling involved in cell growth and survival. Both cohorts receive the combination for three weeks followed by one week off. Researchers measure tumor response. Research biopsies are requested, with defined exemptions.

This phase 2 study plans 30 patients. Alan Ho leads at Memorial Sloan Kettering, New York; seven US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.